GSK with diverse formulations, DovatoㆍCabenuva saw strong growth
[Newsmp] Biktarvy’s (Gilead) monopoly in the HIV treatment market is getting stronger.
Despite the emergence of new types of innovative products that are changing the paradigm of the market, it is still not easy to challenge Biktarvy's dominance.
According to reports on global big pharma’s HIV drug sales, only Biktarvy recorded annual sales of more than KRW 10 trillion, and its sales increased by over KRW 2 trillion last year.
Gilead's Q4 report reveals that Biktarvy's sales in the last quarter of 2021 amounted to KRW 3.86 trillion, approaching KRW 4 trillion. (Based on the exchange rate as of March 10)
The annual sales increased by nearly KRW 2.34 trillion, or 20.5%, to KRW 13.75 trillion compared to 2021, reaching a level comparable to the annual sales of most large HIV drugs.
Along with Biktarvy, Gilead led the growth in the HIV treatment sector, with Descovy recording double-digit growth rates and generating sales of nearly KRW 2.5 trillion.
While Genvoya saw a decline in annual sales of around KRW 600 billion, Truvada by KRW 300 billion, and Odefsey by about KRW 130 billion during the same period, Biktarvy's sales growth was enough to make up for their decrease.
With its new products growing rapidly and compensating for the underperformance of existing ones, GSK is leading a generational shift in the HIV treatment market with its expansion of product formulations, including single-tablet, two-drug regimens, and long-acting injectables.
Although the sales of Triumeq fell from KRW 3.4 trillion to KRW 2.95 trillion, and those of Tivicay dropped from KRW 2.5 trillion to KRW 2.26 trillion, Dovato, a single-tablet, two-drug regimen, increased its sales from KRW 1.43 trillion to KRW 2.25 trillion, offsetting the poor performance of the leading drugs.
In addition, Juluca achieved double-digit growth to exceed KRW 1 trillion in sales, while Cabenuva, a long-acting injectable, is rapidly expanding its sales, breaking the KRW 500 billion mark in its second year after launch.
Prezista and Edurant from Johnson & Johnson are showing stagnation within the dual dominance of Gilead and GSK, while MSD's Isentress has experienced nearly 20% negative growth and annual sales has fallen below KRW 1 trillion.